RT Journal Article
SR Electronic
T1 “SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.02.20186486
DO 10.1101/2020.09.02.20186486
A1 Siddiqui, Samreen
A1 Naushin, Salwa
A1 Pradhan, Shalini
A1 Misra, Archa
A1 Tyagi, Akansha
A1 Loomba, Menka
A1 Waghdhare, Swati
A1 Pandey, Rajesh
A1 Sengupta, Shantanu
A1 Jha, Sujeet
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186486.abstract
AB Background SARS-CoV-2 infection has caused 64,469 deaths in India, with 7, 81, 975 active cases till 30th August 2020, lifting it to 3rd rank globally. To estimate the burden of the disease with time it is important to undertake a longitudinal seroprevalence study which will also help to understand the stability of anti SARS-CoV-2 antibodies. Various studies have been conducted worldwide to assess the antibody stability. However, there is very limited data available from India. Healthcare workers (HCW) are the frontline workforce and more exposed to the COVID-19 infection (SARS-CoV-2) compared to the community. This study was conceptualized with an aim to estimate the seroprevalence in hospital and general population and determine the stability of anti SARS-CoV-2 antibodies in HCW.Methods Staff of a tertiary care hospital in Delhi and individuals visiting that hospital were recruited between April to August 2020. Venous blood sample, demographic, clinical, COVID-19 symptoms, and RT-PCR data was collected from all participants. Serological testing was performed using the electro-chemiluminescence based assay developed by Roche Diagnostics, in Cobas Elecsys 411. Seropositive participants were followed- upto 83 days to check for the presence of antibodies.Results A total of 780 participants were included in this study, which comprised 448 HCW and 332 individuals from the general population. Among the HCW, seroprevalence rates increased from 2.3% in April to 50.6% in July. The cumulative prevalence was 16.5% in HCW and 23.5% (78/332) in the general population with a large number of asymptomatic individuals. Out of 74 seropositive HCWs, 51 were followed-up for the duration of this study. We observed that in all seropositive cases the antibodies were sustained even up to 83 days.Conclusion The cumulative prevalence of seropositivity was lower in HCWs than the general population. There were a large number of asymptomatic cases and the antibodies developed persisted through the duration of the study. More such longitudinal serology studies are needed to better understand the antibody response kinetics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would also like to acknowledge CSIR Project MLP 2003 (Combined Digital Surveillance and Effective COVID-19 Testing Frameworks and Tools) for funding this work. SN acknowledges CSIR for fellowship.RP acknowledges the funding from Fondation Botnar (CLP-0031) and CSIR (MLP-2005) towards the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee of Max Super Speciality Hospital, Saket, New Delhi (REF NO.:RS/MSSH/DDF/SKT-2/IEC/ENDO/20-12).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data relavent to the manuscrpt are with us.